As shown by another research study in advanced melanoma, before and after initiation of nivolumab treatment, there was an increase in the numbers of CD8+ T cells and NK cells in responders vs. non-responders, as well as a decrease in macrophage infiltration [129]. Here, CD8A is linked to melanoma.